Osamu Kurasawa

Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response

Akito Nakamura, Tadahiro Nambu, Shunsuke Ebara et al. · Proceedings of the National Academy of Sciences · 2018 · 170 citations · Full text

Medicine, Oncology, Pharmacology +16

Discovery of a Novel Pyrrole Derivative 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1<i>H</i>-pyrrol-3-yl]-<i>N</i>-methylmethanamine Fumarate (TAK-438) as a Potassium-Competitive Acid Blocker (P-CAB)

Yasuyoshi Arikawa, Haruyuki Nishida, Osamu Kurasawa et al. · Journal of Medicinal Chemistry · 2012 · 157 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor

Kenichi Iwai, Tadahiro Nambu, Ryo Dairiki et al. · Science Advances · 2019 · 70 citations · Full text

Medicine, Oncology, Pharmacology +6

Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers

Haruyuki Nishida, Atsushi Hasuoka, Yasuyoshi Arikawa et al. · Bioorganic & Medicinal Chemistry · 2012 · 46 citations

Pharmacy, Medicinal Chemistry, Pharmacology +12

Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode

Jun Fujimoto, Osamu Kurasawa, Terufumi Takagi et al. · ACS Medicinal Chemistry Letters · 2019 · 41 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13